- Home
- LUCY vs BMRA Comparison
LUCY vs BMRA Comparison
Compare LUCY & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCY
- BMRA
- Stock Information
- Founded
- LUCY 2017
- BMRA 1971
- Country
- LUCY United States
- BMRA United States
- Employees
- LUCY N/A
- BMRA N/A
- Industry
- LUCY Ophthalmic Goods
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- LUCY Health Care
- BMRA Health Care
- Exchange
- LUCY Nasdaq
- BMRA Nasdaq
- Market Cap
- LUCY 8.7M
- BMRA 8.2M
- IPO Year
- LUCY 2022
- BMRA N/A
- Fundamental
- Price
- LUCY $1.89
- BMRA $2.99
- Analyst Decision
- LUCY
- BMRA
- Analyst Count
- LUCY 0
- BMRA 0
- Target Price
- LUCY N/A
- BMRA N/A
- AVG Volume (30 Days)
- LUCY 191.9K
- BMRA 436.0K
- Earning Date
- LUCY 11-11-2025
- BMRA 10-14-2025
- Dividend Yield
- LUCY N/A
- BMRA N/A
- EPS Growth
- LUCY N/A
- BMRA N/A
- EPS
- LUCY N/A
- BMRA N/A
- Revenue
- LUCY $1,978,018.00
- BMRA $5,311,000.00
- Revenue This Year
- LUCY $367.48
- BMRA N/A
- Revenue Next Year
- LUCY $166.67
- BMRA N/A
- P/E Ratio
- LUCY N/A
- BMRA N/A
- Revenue Growth
- LUCY 29.30
- BMRA N/A
- 52 Week Low
- LUCY $1.57
- BMRA $2.08
- 52 Week High
- LUCY $11.16
- BMRA $10.16
- Technical
- Relative Strength Index (RSI)
- LUCY 44.84
- BMRA 46.09
- Support Level
- LUCY $1.82
- BMRA $2.74
- Resistance Level
- LUCY $2.12
- BMRA $3.08
- Average True Range (ATR)
- LUCY 0.10
- BMRA 0.22
- MACD
- LUCY 0.01
- BMRA 0.00
- Stochastic Oscillator
- LUCY 43.90
- BMRA 51.69
About LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.